Stocktoria
Cardio Diagnostics Holdings, Inc. CDIO
Cardio Diagnostics Holdings, Inc. (CDIO) earns a Piotroski F-score of 1/9 (weak financial health), with an Altman Z″ in the distress zone. It does not currently pay a dividend. FY2025 revenue was $14,825 at a -43832.5% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 1/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · distress zone
| Component | Value |
|---|---|
| Working capital / assets | 0.684 |
| Retained earnings / assets | -3.766 |
| EBIT / assets | -0.835 |
| Equity / liabilities | 8.793 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| CDIO | Cardio Diagnostics Holdings, Inc. | 1/9 | -4.17 | — | — |
| CLDX | Celldex Therapeutics, Inc. | 1/9 | 1.9 | — | — |
| IMDX | Insight Molecular Diagnostics Inc. | 3/9 | — | — | — |
| BMRA | BIOMERICA INC | 2/9 | — | — | — |
| NNNN | Anbio Biotechnology | 4/9 | — | 326.5 | — |
| ICCC | IMMUCELL CORP /DE/ | 6/9 | 2.93 | — | +4.3% |
| TKNO | Alpha Teknova, Inc. | 5/9 | -1.59 | — | +7.4% |
About Cardio Diagnostics Holdings, Inc.
Cardio Diagnostics Holdings, Inc. develops and commercializes epigenetics-based clinical tests for cardiovascular disease. The company offers Epi+Gen CHD, a three-year symptomatic coronary heart disease (CHD) risk assessment clinical blood test targeting CHD events, including heart attacks; PrecisionCHD, an integrated epigenetic-genetic clinical blood test for the detection of coronary heart disease; and Actionable Clinical Intelligence, a platform that offers new epigenetic and genetic insights to clinicians prescribing to help improve chronic care management. It also provides CardioInnovate360, a research-use-only solution to support the discovery, development and validation of novel biopharmaceuticals for the assessment and management of cardiovascular diseases; and HeartRisk, a SaaS cardiovascular disease risk intelligence platform. It serves telemedicine providers; provider organizations, such as concierge practices, longevity clinics, and risk-bearing provider organizations; and employer organizations. Cardio Diagnostics Holdings, Inc. was founded in 2017 and is headquartered in Chicago, Illinois.
FAQ
Is CDIO financially healthy?
Cardio Diagnostics Holdings, Inc.'s Piotroski F-score is 1/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the distress zone.
Does CDIO pay a dividend?
No, Cardio Diagnostics Holdings, Inc. does not currently pay a dividend.
How profitable is CDIO?
In FY2025, Cardio Diagnostics Holdings, Inc. had a net margin of -43832.5% and a return on equity of -93.2%.
Is CDIO a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on Cardio Diagnostics Holdings, Inc.: a Piotroski F-score of 1/9, an Altman Z″ in the distress zone. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.